The global Osteoarthritis Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Drug (NSAIDs, Corticosteroids, Hyaluronic Acid Injection), Assistive devices), By Anatomy (Ankle Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, E-Commerce).
The Osteoarthritis Market in 2024 represents a major healthcare challenge, characterized by the progressive degeneration of joint cartilage, inflammation, and functional impairment, affecting millions of individuals worldwide. As the most common form of arthritis, osteoarthritis imposes a significant burden on patients, caregivers, and healthcare systems, leading to pain, stiffness, and reduced mobility in affected joints. In response to this growing epidemic, pharmaceutical companies focus on developing disease-modifying therapies, symptomatic relief medications, and regenerative treatments aimed at preserving joint integrity, alleviating symptoms, and improving quality of life for osteoarthritis patients. From nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics to intra-articular injections, biologic agents, and regenerative medicine approaches, the market offers a diverse array of pharmacological and nonpharmacological interventions tailored to individual patient needs and disease severity, reflecting a holistic approach to osteoarthritis management.
The global Osteoarthritis Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Osteoarthritis Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Osteoarthritis Industry include- Bayer AG, Biosplice Therapeutics, Centrexion Therapeutics, Eli Lilly and Company, GlaxoSmithKline plc, Janssen, Kolon TissueGene, Merck, Novartis AG, Organogenesis Holdings, Pacira BioSciences, Pfizer Inc, Techfields Pharma.
A prominent trend in the Osteoarthritis Market is the rising aging population and lifestyle-related factors contributing to the prevalence of osteoarthritis (OA). With a growing number of elderly individuals globally and an increase in sedentary lifestyles, the incidence of OA, particularly in weight-bearing joints, is on the rise. This trend is driving the demand for effective treatment options and management strategies to address the symptoms and progression of osteoarthritis.
The market for osteoarthritis is driven by continuous advancements in treatment modalities, including pharmacological interventions, non-pharmacological therapies, and surgical procedures. Pharmaceutical companies and medical device manufacturers are investing in research and development to create innovative drugs, biologics, and devices aimed at providing symptomatic relief, improving joint function, and slowing down the progression of osteoarthritis. Advancements such as regenerative medicine techniques, minimally invasive surgeries, and precision medicine approaches are driving market growth.
An opportunity in the Osteoarthritis Market lies in focusing on personalized and regenerative therapies for osteoarthritis management. With a better understanding of genetic factors, biomarkers, and disease mechanisms, there is an opportunity to develop personalized treatment plans tailored to individual patient needs. Additionally, regenerative therapies such as stem cell therapy, platelet-rich plasma (PRP) injections, and tissue engineering offer potential opportunities for tissue repair, cartilage regeneration, and improved outcomes in osteoarthritis patients. Collaborative efforts between pharmaceutical companies, healthcare providers, and research institutions can drive innovation in personalized and regenerative approaches for osteoarthritis management.
Among the segments listed, the fastest-growing category for osteoarthritis treatment is Hyaluronic Acid Injection for Knee Osteoarthritis. Hyaluronic acid injections, also known as viscosupplementation, involve injecting a gel-like fluid into the knee joint to provide lubrication, cushioning, and relief from pain and stiffness associated with osteoarthritis. This treatment aims to restore the natural balance of hyaluronic acid in the joint fluid, which tends to decrease in osteoarthritis patients, leading to joint pain and inflammation. The rapid growth in the demand for hyaluronic acid injections can be attributed to several factors, including the aging population, increasing prevalence of knee osteoarthritis, rising awareness about non-surgical treatment options, and advancements in medical technology leading to improved formulations and delivery methods. As patients seek alternatives to surgery and traditional pain medications, hyaluronic acid injections have emerged as a popular choice for managing knee osteoarthritis symptoms, driving the growth of this segment in both hospital and retail pharmacy settings, as well as through online channels.
By Type
Drug
-Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-Corticosteroids
-Hyaluronic Acid Injection
-Others
Assistive devices
By Anatomy
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Bayer AG
Biosplice Therapeutics
Centrexion Therapeutics
Eli Lilly and Company
GlaxoSmithKline plc
Janssen
Kolon TissueGene
Merck
Novartis AG
Organogenesis Holdings
Pacira BioSciences
Pfizer Inc
Techfields Pharma
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Osteoarthritis Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Osteoarthritis Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Osteoarthritis Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Osteoarthritis Market Size Outlook, $ Million, 2021 to 2030
3.2 Osteoarthritis Market Outlook by Type, $ Million, 2021 to 2030
3.3 Osteoarthritis Market Outlook by Product, $ Million, 2021 to 2030
3.4 Osteoarthritis Market Outlook by Application, $ Million, 2021 to 2030
3.5 Osteoarthritis Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Osteoarthritis Industry
4.2 Key Market Trends in Osteoarthritis Industry
4.3 Potential Opportunities in Osteoarthritis Industry
4.4 Key Challenges in Osteoarthritis Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Osteoarthritis Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Osteoarthritis Market Outlook by Segments
7.1 Osteoarthritis Market Outlook by Segments, $ Million, 2021- 2030
By Type
Drug
-Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-Corticosteroids
-Hyaluronic Acid Injection
-Others
Assistive devices
By Anatomy
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
8 North America Osteoarthritis Market Analysis and Outlook To 2030
8.1 Introduction to North America Osteoarthritis Markets in 2024
8.2 North America Osteoarthritis Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Osteoarthritis Market size Outlook by Segments, 2021-2030
By Type
Drug
-Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-Corticosteroids
-Hyaluronic Acid Injection
-Others
Assistive devices
By Anatomy
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
9 Europe Osteoarthritis Market Analysis and Outlook To 2030
9.1 Introduction to Europe Osteoarthritis Markets in 2024
9.2 Europe Osteoarthritis Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Osteoarthritis Market Size Outlook by Segments, 2021-2030
By Type
Drug
-Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-Corticosteroids
-Hyaluronic Acid Injection
-Others
Assistive devices
By Anatomy
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
10 Asia Pacific Osteoarthritis Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Osteoarthritis Markets in 2024
10.2 Asia Pacific Osteoarthritis Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Osteoarthritis Market size Outlook by Segments, 2021-2030
By Type
Drug
-Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-Corticosteroids
-Hyaluronic Acid Injection
-Others
Assistive devices
By Anatomy
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
11 South America Osteoarthritis Market Analysis and Outlook To 2030
11.1 Introduction to South America Osteoarthritis Markets in 2024
11.2 South America Osteoarthritis Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Osteoarthritis Market size Outlook by Segments, 2021-2030
By Type
Drug
-Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-Corticosteroids
-Hyaluronic Acid Injection
-Others
Assistive devices
By Anatomy
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
12 Middle East and Africa Osteoarthritis Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Osteoarthritis Markets in 2024
12.2 Middle East and Africa Osteoarthritis Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Osteoarthritis Market size Outlook by Segments, 2021-2030
By Type
Drug
-Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-Corticosteroids
-Hyaluronic Acid Injection
-Others
Assistive devices
By Anatomy
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Bayer AG
Biosplice Therapeutics
Centrexion Therapeutics
Eli Lilly and Company
GlaxoSmithKline plc
Janssen
Kolon TissueGene
Merck
Novartis AG
Organogenesis Holdings
Pacira BioSciences
Pfizer Inc
Techfields Pharma
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Type
Drug
-Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-Corticosteroids
-Hyaluronic Acid Injection
-Others
Assistive devices
By Anatomy
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
The global Osteoarthritis Market is one of the lucrative growth markets, poised to register a 5.6% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Bayer AG, Biosplice Therapeutics, Centrexion Therapeutics, Eli Lilly and Company, GlaxoSmithKline plc, Janssen, Kolon TissueGene, Merck, Novartis AG, Organogenesis Holdings, Pacira BioSciences, Pfizer Inc, Techfields Pharma
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume